These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36830286)

  • 21. Multiomics characterization of methicillin-resistant Staphylococcus aureus (MRSA) isolates with heterogeneous intermediate resistance to vancomycin (hVISA) in Latin America.
    Castro BE; Rios R; Carvajal LP; Vargas ML; Cala MP; León L; Hanson B; Dinh AQ; Ortega-Recalde O; Seas C; Munita JM; Arias CA; Rincon S; Reyes J; Diaz L
    J Antimicrob Chemother; 2022 Dec; 78(1):122-132. PubMed ID: 36322484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IS
    Kuroda M; Sekizuka T; Matsui H; Ohsuga J; Ohshima T; Hanaki H
    Front Microbiol; 2019; 10():1882. PubMed ID: 31474962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High prevalence of a globally disseminated hypervirulent clone, Staphylococcus aureus CC121, with reduced vancomycin susceptibility in community settings in China.
    Shen P; Zhou K; Wang Y; Song J; Liu Y; Zhou Y; Xiao Y
    J Antimicrob Chemother; 2019 Sep; 74(9):2537-2543. PubMed ID: 31203362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3.
    Matsuo M; Cui L; Kim J; Hiramatsu K
    Antimicrob Agents Chemother; 2013 Dec; 57(12):5843-53. PubMed ID: 24018261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Daptomycin and vancomycin heteroresistance revealed among CC5-SCCmecII MRSA clone and in vitro evaluation of treatment alternatives.
    Okado JB; Avaca-Crusca JS; Oliveira AL; Dabul ANG; Camargo ILBDC
    J Glob Antimicrob Resist; 2018 Sep; 14():209-216. PubMed ID: 29753135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced susceptibility to vancomycin in isogenic Staphylococcus aureus strains of sequence type 59: tracking evolution and identifying mutations by whole-genome sequencing.
    Chen CJ; Lin MH; Shu JC; Lu JJ
    J Antimicrob Chemother; 2014 Feb; 69(2):349-54. PubMed ID: 24092658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methicillin-resistant
    Lin CY; Wang JH; Lin KH; Ho YL; Ho CM
    Ci Ji Yi Xue Za Zhi; 2018; 30(3):135-140. PubMed ID: 30069120
    [No Abstract]   [Full Text] [Related]  

  • 28. Synergistic effect of vancomycin combined with cefotaxime, imipenem, or meropenem against Staphylococcus aureus with reduced susceptibility to vancomycin.
    Srisrattakarn A; Chaiyapoke C; Booncharoen S; Wongthong S; Chanawong A; Tippayawat P; Tavichakorntrakool R; Lulitanond A
    Turk J Med Sci; 2021 Aug; 51(4):2150-2158. PubMed ID: 33705643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA.
    Horne KC; Howden BP; Grabsch EA; Graham M; Ward PB; Xie S; Mayall BC; Johnson PD; Grayson ML
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3447-52. PubMed ID: 19506056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus Isolates and vancomycin-intermediate S. aureus isolates in vitro.
    Dilworth TJ; Sliwinski J; Ryan K; Dodd M; Mercier RC
    Antimicrob Agents Chemother; 2014; 58(2):1028-33. PubMed ID: 24277036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. β-Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible Staphylococcus aureus, Vancomycin-Intermediate S. aureus (VISA), and Heterogeneous VISA.
    Tran N; Rybak MJ
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical, microbiological, and genetic characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a teaching hospital.
    Di Gregorio S; Perazzi B; Ordoñez AM; De Gregorio S; Foccoli M; Lasala MB; García S; Vay C; Famiglietti A; Mollerach M
    Microb Drug Resist; 2015 Feb; 21(1):25-34. PubMed ID: 25535825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduced Susceptibility and Resistance to Vancomycin of Staphylococcus aureus: A Review of Global Incidence Patterns and Related Genetic Mechanisms.
    Unni S; Siddiqui TJ; Bidaisee S
    Cureus; 2021 Oct; 13(10):e18925. PubMed ID: 34812309
    [No Abstract]   [Full Text] [Related]  

  • 34. Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus.
    Hafer C; Lin Y; Kornblum J; Lowy FD; Uhlemann AC
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5845-51. PubMed ID: 22948864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phenotypic characteristics and comparative proteomics of Staphylococcus aureus strains with different vancomycin-resistance levels.
    Sirichoat A; Lulitanond A; Kanlaya R; Tavichakorntrakool R; Chanawong A; Wongthong S; Thongboonkerd V
    Diagn Microbiol Infect Dis; 2016 Dec; 86(4):340-344. PubMed ID: 27717648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis.
    Shariati A; Dadashi M; Moghadam MT; van Belkum A; Yaslianifard S; Darban-Sarokhalil D
    Sci Rep; 2020 Jul; 10(1):12689. PubMed ID: 32728110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of intermediately vancomycin-susceptible and heterogeneous Staphylococcus aureus isolates: comparison of Etest and Agar screening methods.
    Riederer K; Shemes S; Chase P; Musta A; Mar A; Khatib R
    J Clin Microbiol; 2011 Jun; 49(6):2147-50. PubMed ID: 21490190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey.
    Sancak B; Yagci S; Gür D; Gülay Z; Ogunc D; Söyletir G; Yalcin AN; Dündar DO; Topçu AW; Aksit F; Usluer G; Ozakin C; Akalin H; Hayran M; Korten V
    BMC Infect Dis; 2013 Dec; 13():583. PubMed ID: 24325260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.
    Bhalodi AA; Hagihara M; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2014; 58(2):672-7. PubMed ID: 24217694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
    Leonard SN; Rybak MJ
    J Antimicrob Chemother; 2009 Jan; 63(1):155-60. PubMed ID: 18984644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.